HC Wainwright Issues Pessimistic Forecast for Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price

Karyopharm Therapeutics (NASDAQ:KPTI) had its price target lowered by research analysts at HC Wainwright from $15.00 to $8.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective would suggest a potential upside of 47.06% from the company’s current price.

Other research analysts have also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Karyopharm Therapeutics in a report on Monday, December 29th. Cantor Fitzgerald started coverage on Karyopharm Therapeutics in a research note on Thursday, February 5th. They issued an “overweight” rating on the stock. Rodman & Renshaw upgraded Karyopharm Therapeutics to a “strong-buy” rating in a report on Tuesday, March 10th. Piper Sandler reissued an “overweight” rating and set a $12.00 price objective on shares of Karyopharm Therapeutics in a research report on Wednesday, December 17th. Finally, The Goldman Sachs Group set a $12.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.71.

Karyopharm Therapeutics Trading Down 18.3%

Karyopharm Therapeutics stock opened at $5.44 on Wednesday. The company has a 50-day moving average price of $7.80 and a 200 day moving average price of $6.85. Karyopharm Therapeutics has a 12-month low of $3.51 and a 12-month high of $10.99. The stock has a market cap of $99.77 million, a P/E ratio of -0.33 and a beta of 0.13.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Friday, February 13th. The company reported ($2.23) earnings per share for the quarter, beating the consensus estimate of ($2.26) by $0.03. The firm had revenue of $34.08 million during the quarter, compared to analyst estimates of $33.16 million. As a group, analysts forecast that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Baird Financial Group Inc. acquired a new stake in Karyopharm Therapeutics during the 2nd quarter worth approximately $45,000. XTX Topco Ltd acquired a new position in shares of Karyopharm Therapeutics in the second quarter worth $56,000. Corient Private Wealth LLC purchased a new stake in shares of Karyopharm Therapeutics during the fourth quarter worth $74,000. Tudor Investment Corp ET AL purchased a new stake in shares of Karyopharm Therapeutics during the fourth quarter worth $95,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Karyopharm Therapeutics in the fourth quarter valued at $135,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

Key Headlines Impacting Karyopharm Therapeutics

Here are the key news stories impacting Karyopharm Therapeutics this week:

• Positive Sentiment: SENTRY met one co‑primary endpoint (statistically significant spleen volume reduction — SVR35) and showed a promising overall survival signal and early reductions in variant allele frequency (VAF), findings that support potential clinical benefit versus ruxolitinib. PR Newswire: SENTRY results
• Positive Sentiment: The company says it will meet with the FDA to discuss the totality of SENTRY data and potential supplemental NDA (sNDA)/label expansion for Xpovio in myelofibrosis — a clear pathway to commercialization upside if regulators are receptive. MSN: label expansion
• Neutral Sentiment: The company held a conference call and trading was briefly halted for “news pending” around the results — expect short‑term volatility as more detail and analyst takes emerge. PR Newswire: conference call
• Negative Sentiment: SENTRY missed its second co‑primary endpoint (absolute total symptom score — Abs‑TSS), which raises questions about the breadth of clinical benefit and complicates regulatory discussions and labeling prospects. PR Newswire: missed Abs‑TSS
• Negative Sentiment: Karyopharm announced a $30M private placement with RA Capital (with up to ~$44M additional if warrants are exercised). The financing provides near‑term cash but is dilutive and triggered a sharp selloff in some sessions. PR Newswire: financing Blockonomi: market reaction
• Negative Sentiment: Short interest rose meaningfully in March (reports of ~3.59M shares short, ~20% of shares outstanding at one point), adding bearish pressure and increasing the risk of continued volatility into upcoming catalysts.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.